Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 2/20 | 0.44 |
| ▸ | FNTB | P49356 | 2/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6010238 | 0.85 | LMNA (0.49) | LMNALTA4HALDH1A1NPSR1FOLH1 | |
| SCHEMBL5332357 | 0.84 | MME (0.46) | LMNAFOLH1 | |
| SCHEMBL2549621 | 0.83 | LMNA (0.51) | LMNACA2CA1FNTAFNTB | |
| SCHEMBL14500882 | 0.83 | LMNA (0.51) | LMNACA2CA1FNTAFNTB | |
| SCHEMBL5330523 | 0.83 | MME (0.41) | LMNA | |
| SCHEMBL29204872 | 0.82 | LMNA (0.53) | LMNALTA4HALDH1A1NPSR1FOLH1 | |
| SCHEMBL5325870 | 0.82 | MME (0.40) | LMNALTA4H | |
| SCHEMBL11434654 | 0.81 | FNTA (0.49) | LTA4HFNTAFNTBPGGT1B | |
| SCHEMBL4957057 | 0.81 | LMNA (0.51) | LMNALTA4HALDH1A1NPSR1FOLH1 | |
| SCHEMBL4572626 | 0.81 | LMNA (0.51) | LMNALTA4HALDH1A1NPSR1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007147155-A1 | POLYOL ESTER COMPOUNDS | NOVUS INTERNATIONAL INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070292485-A1 | POLYOL ESTER COMPOUNDS | NOVUS INTERNATIONAL INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070292485-A1 | POLYOL ESTER COMPOUNDS | PNLIP, ELOVL1, ELOVL5 | LMNA 1572/4885LTA4H 685/4885ALDH1A1 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.